A U.S. Senate subcommittee has opened a "preliminary inquiry" into Mylan Pharmaceuticals' price increases on its allergic reaction treatment EpiPen, Sens. Rob Portman (R, Ohio) and Claire McCaskill (D, Mo.) said Wednesday afternoon. The company's sixfold price increases on the EpiPen over the last several years sparked public outrage and condemnation by various lawmakers last month. "Our review of this matter will be robust, thorough and bipartisan," the two senators said. Mylan's shares dropped 7.8% over the last three months, compared with a 3.5% rise in the S&P 500 .
Copyright © 2016 MarketWatch, Inc.